Cytokinetics reports Q3 EPS ($2.55), consensus ($1.57)

Reports Q3 revenue $1.94M, consensus $6.05M. The net loss for the third quarter of 2025 includes the debt conversion expense of $121.2M due to the induced exchange of $399.5M of aggregate principal amount of the 2027 Notes. “I’m pleased that our teams continue to demonstrate strong execution and sustained momentum as we approach the PDUFA date for the aficamten NDA. Our commercial preparations have been deliberate and strategic, positioning us well for this milestone,” said Robert I. Blum, Cytokinetics (CYTK)’ President and Chief Executive Officer. “During the third quarter, we expanded the evidence base for aficamten, with MAPLE-HCM further reinforcing the potential of aficamten in patients with obstructive HCM. With a strong balance sheet, clear focus, and a deep commitment to our mission, we are entering this pivotal transformation toward potential commercialization with confidence, alignment and purpose as we aim to deliver on the promise of translating our science to a new medicine for patients.”